Log In
BCIQ
Print this Print this
 

ATL1101

  Manage Alerts
Collapse Summary General Information
Company Antisense Therapeutics Ltd.
DescriptionSecond-generation antisense inhibitor of insulin-like growth factor-1 (IGF-1) receptor (IGF1R; CD221)
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today